UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange
Act of 1934
FEBRUARY 2, 2006
NOVO
NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
|
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes [ ]
|
No [X]
|
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________
Director/PDMR Shareholding
Trading in Novo Nordisk shares by board members, executives and associated persons as reported to Novo Nordisk on 31 January 2006
In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
Please find below a statement of such trading in shares issued by Novo Nordisk.
|
|
|
| Name | Kurt Anker Nielsen |
|
|
|
| Reason for reporting | Board Member |
|
|
|
| Financial instrument and ID code | Novo Nordisk B shares DK 001028081 |
|
|
|
| Type of transaction | Sale of shares |
|
|
|
| Date of transaction | 31 January 2006 |
|
|
|
| Place of transaction | Copenhagen Stock Exchange |
|
|
|
| Volume of transaction | 5,000 shares |
|
|
|
| Total value of transaction | DKK 1,732,500 |
|
|
|
Definitions and background information:
Publication
Publication
shall take place the day after Novo Nordisk receives sufficient information
on the trading. Publication is only required when the total amount of transactions
of a specific board member/executive and his/her associated persons in any
one calendar year has reached 5,000 euros.
Who are
board members, executives and associated persons?
Board
members and executives are members of the Board of Directors and Executive
Management, respectively, of Novo Nordisk A/S. Associated persons are defined
as the following persons associated to a board member/executive: 1) spouse
or cohabitant, 2) children under the age of 18 years, 3) relatives defined
as brothers, sisters, parents, grandparents etc, children, grandchildren
etc who have shared the same household with a board member/executive for
at least one year, and 4) any legal person, including a company, a foundation
or a partnership, which is controlled directly or indirectly by a board
member/executive and/or a person mentioned in 1)-3), or to which a board
member/executive and/or a person mentioned in 1)-3) has managerial responsibilities
or economic interests substantially equivalent to the legal person.
What is
trading/transaction?
Trading
is any kind of transaction, including shares purchased or otherwise acquired,
shares sold or otherwise disposed, gifts, mortgages and grants and exercise
of options, but not heritage.
What is
financial instrument and ID code?
Financial
instrument includes shares listed on the Copenhagen Stock Exchange and London
Stock Exchange as well as ADRs listed on New York Stock Exchange, except
for ADRs held in 401(k) retirement plan by US-based employees. The ID code
is the code (ISIN DK001028081) of the Novo Nordisk share on the Copenhagen
Stock Exchange, the code (NVOB) on London Stock Exchange or the code (NVO)
on New York Stock Exchange.
What is
date and place of transaction?
Date of
transaction is the actual transaction date. The place of transaction is
the actual place of transaction, ie Copenhagen Stock Exchange, London Stock
Exchange or New York Stock Exchange.
What is
volume and value of transaction?
The volume
of transaction is the number of shares (of DKK 2 nominal value) or other
financial instruments traded. The transaction value is the number of shares
traded multiplied by the transaction price. The exchange rate of the Danish
Central Bank (Nationalbanken) on the date of transaction is used for calculating
the transaction value in DKK in case of shares traded on London Stock Exchange
and ADRs listed on New York Stock Exchange.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 22,000 full-time employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
For further information please contact:
| Media: |
Investors:
|
| Outside North America: | Outside North America: |
| Elin K Hansen | Mogens Thorsager Jensen |
| Tel (direct): (+45) 4442 3450 | Tel (direct): (+45) 4442 7945 |
| Christian Qvist Frandsen | |
| Tel (direct): (+45) 4443 5182 | |
| In North America: | In North America: |
| Susan T Jackson | Mads Veggerby Lausten |
| Tel (direct): (+1) 609 919 7776 | Tel (direct): (+1) 609 919 7937 |
Stock Exchange Announcement no 4 / 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: FEBRUARY 2, 2006 |
NOVO NORDISK A/S Lars Rebien Sørensen, President and Chief Executive Officer |